April 2 (UPI) -- Heart disease experts are hailing the results of a clinical trial that showed a strongly positive performance by Eli Lilly 's drug lepodisiran, which inhibits the body's production of an especially dangerous type of "bad" cholesterol. Two eminent cardiologists told UPI the study results are exciting and hold promise to change the medical landscape for tens of millions of Americans who are genetically predisposed to have elevated levels of a pernicious cholesterol variant known